Our data suggests that OC2 may be involved in the development of drug resistance in the NE molecular subtypes of SCLC and that OC2 suppression may serve to inhibit the emergence of treatment-resistant, non-NE subtypes of SCLC. Here, ONECUT2 is linked to small cell lung carcinoma.